AI ‘the only way’ for healthcare, says the VA’s first director of AI

The VA’s inaugural director of artificial intelligence believes the technology is “the only way” to move healthcare closer to its perennial dual goals of reducing costs and providing better care.

“AI is key to really taking advantage of [big] data to help vets and potentially others as well,” says Gil Alterovitz, PhD, who was installed last week.

Speaking on his guiding vision with a writer in the VA’s communications division, Alterovitz pointed to the Million Veteran Program (MVP) as a proven example of how the VA can leverage data to improve health at the population level.

MVP has gathered genomic and health data on more than 750,000 willing veterans, making it one of the world’s largest genomic databases, and it’s aiming to hit 1 million sometime soon.

Alterovitz, a Harvard Medical School professor who helped author the White House’s updated AI strategic plan released in June, says fostering partnerships with AI experts will be a priority.

“There’s a lot of exciting work in imaging diagnostics with deep learning outside the VA and lots of potential within VA,” he says. “But there’s not a lot of activity right now within VA. It’s perhaps a little under-represented.”

He also tells the writer he believes AI in healthcare won’t replace physicians or other healthcare workers.

Instead, he says, the drive to move healthcare forward with AI is “about establishing a human-AI collaborative environment.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.